SI-BONE FY2025 EPS Estimate Lowered by Cantor Fitzgerald

SI-BONE, Inc. (NASDAQ:SIBN) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of SI-BONE in a report issued on Tuesday, February 25th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.64) per share for the year, down from their previous estimate of ($0.19). Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

Other analysts also recently issued reports about the stock. Truist Financial reiterated a “buy” rating and issued a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research report on Tuesday. Needham & Company LLC lifted their price target on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE has a consensus rating of “Buy” and an average target price of $24.50.

SI-BONE Price Performance

Shares of SIBN opened at $17.81 on Thursday. The stock has a fifty day moving average price of $16.01 and a 200 day moving average price of $14.76. The company has a market cap of $746.92 million, a P/E ratio of -19.36 and a beta of 1.17. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE has a 12 month low of $11.70 and a 12 month high of $19.16.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%.

Insider Buying and Selling at SI-BONE

In other news, CFO Anshul Maheshwari sold 5,304 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now owns 189,319 shares in the company, valued at $2,633,427.29. This represents a 2.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares in the company, valued at approximately $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,311 shares of company stock valued at $130,356. Company insiders own 3.90% of the company’s stock.

Institutional Trading of SI-BONE

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC grew its position in SI-BONE by 29.0% in the third quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock worth $1,081,000 after buying an additional 17,410 shares during the last quarter. Millrace Asset Group Inc. bought a new stake in shares of SI-BONE during the 3rd quarter worth $1,056,000. Champlain Investment Partners LLC grew its holdings in shares of SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after acquiring an additional 358,821 shares during the last quarter. Impax Asset Management Group plc raised its position in shares of SI-BONE by 41.3% during the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock worth $10,604,000 after purchasing an additional 221,604 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in shares of SI-BONE by 9.4% during the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock valued at $265,000 after purchasing an additional 1,745 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.